Jenner Investigator, Group Head / PI, Fellow and Supervisor in Dengue and vivax malaria vaccine development. University of Oxford, UK
Associate Professor, Wellcome Trust Career Development Fellow, CONACyT SNI II. In recent years, I have contributed to the development of one of the leading vaccine candidates for P. falciparum malaria that targets the parasite at the liver, where it stops and multiplies before entering the blood (pre-erythrocytic or liver-stage vaccines). This strategy uses novel recombinant viral vectors (ChAd63 and Modified Vaccinia Ankara, MVA) expressing the recombinant antigen TRAP. By exploiting their extraordinary ability to stimulate both arms of the adaptive immune response –antibodies and T cells-, we can elicit immune responses able to provide outstanding protection in a sporozoite challenge that mimics the infection process by which a mosquito inoculates parasites into a mammalian host. My research contributed to the understanding of mechanisms responsible for the extraordinary protecti ve efficacy of recombinant viral vectors, laying the basis for their optimal use as malaria vaccines. My ongoing research focuses on the development of a novel malaria vaccine against P. vivax using recombinant viral vectors expressing pre-erythrocytic antigens. An additional research interest consists on the development of vaccines for dengue using recombinant viral vectors.
Speaker at session 7, 3rd day, November 23th: Novel, yet simple and efficient vaccine technologies to tackle emerging arbovirus diseases: Zika, Dengue and Chikungunya.